Cellectar Biosciences to Present Updated Phase 2b CLOVER WaM Data at ASH Annual Meeting

Article summary

Cellectar Biosciences announced it will present three posters at the American Society of Hematology (ASH) Annual Meeting in December, featuring updated 12-month follow-up data for its lead radiopharmaceutical candidate, iopofosine I 131.